InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-03-31 | Daniel Goldman(D-NY10) | house | Sale | $1,001 - $15,000 |
| 2023-02-27 | Daniel Goldman(D-NY10) | house | Purchase | $1,001 - $15,000 |
No financial data available for GRFS.
Company may not file with SEC or CIK is unresolved.
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
European Equities Traded in the US as American Depositary Receipts Start Week Lower
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Is Grifols (BME:GRF) A Potential Opportunity After A 59% Five Year Share Price Slide
Kawasaki Disease Market Analysis and Global Forecast Report 2025-2035 Featuring Prominent Players - Takeda Pharmaceutical, CSL Behring, Grifols, ADMA Biologics, and Octapharma
Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson’s Disease Detection
Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
Grifols facing restrictions in Canada after plasma donor deaths
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Biggest stock movers Wednesday: CHWY, MU, ARM, and more
Grifols considers IPO of part of its US biopharma business